Wenchuan Guo

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Jeremy S. Abramson, David J. Straus, Nancy L. Bartlett, John M. Burke et autres

us, es, it, au (code pays fourni par la source)

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary

Jeremy Abramson, D Straus, N R Bartlett, John M. Burke et autres

us, es, hu, it, au (code pays fourni par la source)

Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma

Jeremy Abramson, D. J. Straus, Nancy L. Bartlett, John M. Burke et autres

us, es, hu, it, au (code pays fourni par la source)

POSTER: HL-1025 Circulating Tumor DNA (ctDNA) Assessment in Patients With Early-Stage Classical Hodgkin Lymphoma (cHL) Treated With a Combination of Brentuximab Vedotin (BV) and Nivolumab

Ryan C. Lynch, Nancy Barlett, John M. Burke, Yuliya Linhares et autres

HL-1025: Circulating Tumor DNA (ctDNA) Assessment in Patients With Early-Stage Classical Hodgkin Lymphoma (cHL) Treated With a Combination of Brentuximab Vedotin (BV) and Nivolumab

Ryan C. Lynch, Nancy Barlett, John M. Burke, Yuliya Linhares et autres

418 | CIRCULATING TUMOR DNA ASSESSMENT IN PATIENTS WITH EARLY‐STAGE CLASSICAL HODGKIN LYMPHOMA TREATED WITH COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB

Ryan C. Lynch, Nancy L. Bartlett, J. M. Burke, Y. Linhares et autres

us, es, pl, au (code pays fourni par la source)

Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab.

Ryan C. Lynch, Nancy L. Bartlett, John M. Burke, Yuliya Linhares et autres

us, es, pl, au (code pays fourni par la source)

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

Hun Ju Lee, Radhakrishnan Ramchandren, Judah Friedman, Jason M. Melear et autres

us, gb (code pays fourni par la source)

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Jeremy S. Abramson, David J. Straus, Nancy L. Bartlett, John M. Burke et autres

us, es, pl, it, au (code pays fourni par la source)

Table S1 from Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma

Zufei Zhang, Daping Zhang, Wenchuan Guo, Keenan Fenton et autres

Figure S2 from Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma

Zufei Zhang, Daping Zhang, Wenchuan Guo, Keenan Fenton et autres

Figure S1 from Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma

Zufei Zhang, Daping Zhang, Wenchuan Guo, Keenan Fenton et autres